Browse KCNH5

Summary
SymbolKCNH5
Namepotassium channel, voltage gated eag related subfamily H, member 5
Aliases Kv10.2; H-EAG2; eag2; potassium voltage-gated channel, subfamily H (eag-related), member 5; hEAG2; ether-a-g ......
Chromosomal Location14q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Multi-pass membrane protein.
Domain PF00027 Cyclic nucleotide-binding domain
PF00520 Ion transport protein
PF13426 PAS domain
Function

Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a non-inactivating outward rectifying current. Channel properties may be modulated by cAMP and subunit assembly.

> Gene Ontology
 
Biological Process GO:0000086 G2/M transition of mitotic cell cycle
GO:0000160 phosphorelay signal transduction system
GO:0006813 potassium ion transport
GO:0007346 regulation of mitotic cell cycle
GO:0010389 regulation of G2/M transition of mitotic cell cycle
GO:0015672 monovalent inorganic cation transport
GO:0034762 regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0042391 regulation of membrane potential
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044839 cell cycle G2/M phase transition
GO:0071804 cellular potassium ion transport
GO:0071805 potassium ion transmembrane transport
GO:1901987 regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1902749 regulation of cell cycle G2/M phase transition
Molecular Function GO:0000155 phosphorelay sensor kinase activity
GO:0004673 protein histidine kinase activity
GO:0005216 ion channel activity
GO:0005244 voltage-gated ion channel activity
GO:0005249 voltage-gated potassium channel activity
GO:0005261 cation channel activity
GO:0005267 potassium channel activity
GO:0005516 calmodulin binding
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015079 potassium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0016775 phosphotransferase activity, nitrogenous group as acceptor
GO:0022803 passive transmembrane transporter activity
GO:0022832 voltage-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0022843 voltage-gated cation channel activity
GO:0044325 ion channel binding
GO:0046873 metal ion transmembrane transporter activity
GO:0046982 protein heterodimerization activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-112316: Neuronal System
R-HSA-1296071: Potassium Channels
R-HSA-1296072: Voltage gated Potassium channels
Summary
SymbolKCNH5
Namepotassium channel, voltage gated eag related subfamily H, member 5
Aliases Kv10.2; H-EAG2; eag2; potassium voltage-gated channel, subfamily H (eag-related), member 5; hEAG2; ether-a-g ......
Chromosomal Location14q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KCNH5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolKCNH5
Namepotassium channel, voltage gated eag related subfamily H, member 5
Aliases Kv10.2; H-EAG2; eag2; potassium voltage-gated channel, subfamily H (eag-related), member 5; hEAG2; ether-a-g ......
Chromosomal Location14q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KCNH5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKCNH5
Namepotassium channel, voltage gated eag related subfamily H, member 5
Aliases Kv10.2; H-EAG2; eag2; potassium voltage-gated channel, subfamily H (eag-related), member 5; hEAG2; ether-a-g ......
Chromosomal Location14q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KCNH5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4380.476
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1410.906
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8120.576
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.1930.148
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-2.1820.173
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0590.976
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4330.26
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KCNH5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141728.6028.60.0318
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103300300.528
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.28.2140.0808
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.210.2120.181
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211733.35.927.40.0534
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131146.29.137.10.0778
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKCNH5
Namepotassium channel, voltage gated eag related subfamily H, member 5
Aliases Kv10.2; H-EAG2; eag2; potassium voltage-gated channel, subfamily H (eag-related), member 5; hEAG2; ether-a-g ......
Chromosomal Location14q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KCNH5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKCNH5
Namepotassium channel, voltage gated eag related subfamily H, member 5
Aliases Kv10.2; H-EAG2; eag2; potassium voltage-gated channel, subfamily H (eag-related), member 5; hEAG2; ether-a-g ......
Chromosomal Location14q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KCNH5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KCNH5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKCNH5
Namepotassium channel, voltage gated eag related subfamily H, member 5
Aliases Kv10.2; H-EAG2; eag2; potassium voltage-gated channel, subfamily H (eag-related), member 5; hEAG2; ether-a-g ......
Chromosomal Location14q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KCNH5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKCNH5
Namepotassium channel, voltage gated eag related subfamily H, member 5
Aliases Kv10.2; H-EAG2; eag2; potassium voltage-gated channel, subfamily H (eag-related), member 5; hEAG2; ether-a-g ......
Chromosomal Location14q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KCNH5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKCNH5
Namepotassium channel, voltage gated eag related subfamily H, member 5
Aliases Kv10.2; H-EAG2; eag2; potassium voltage-gated channel, subfamily H (eag-related), member 5; hEAG2; ether-a-g ......
Chromosomal Location14q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KCNH5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKCNH5
Namepotassium channel, voltage gated eag related subfamily H, member 5
Aliases Kv10.2; H-EAG2; eag2; potassium voltage-gated channel, subfamily H (eag-related), member 5; hEAG2; ether-a-g ......
Chromosomal Location14q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KCNH5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.